Alterations in estrogen signaling can be linked to resistance against PI3K pathway inhibitors, particularly in estrogen receptor (ER)-positive breast cancer; however, whether this translates to gynecological cancers sensitive to hormones is unknown. The gene discussed is ESR1; the disease is breast carcinoma.